Assessing the protective role of allergic disease in gastrointestinal tract cancers using Mendelian randomization analysis

To the Editor,

Immune hypersensitivity featured among allergic individuals has been proposed to enhance immune surveillance, thereby inhibiting abnormal cell growth and thus reduce cancer risk.\(^1\,^2\) Similarly, the prophylaxis theory suggests that allergy symptoms may prevent cancer development by removing potential carcinogens.\(^2\) This hypothesis envisages a preventive role specifically for cancers of tissues that interface with the external environment, such as gastrointestinal tract cancers.\(^2\) A reduced risk of gastrointestinal tract cancer among individuals with self-reported allergic conditions has been observed in several but not all observational studies.\(^3\,^4\) However, whether the associations are causal remains unclear as observational studies are prone to residual confounding. Therefore, we conducted a Mendelian randomization study\(^5\) to determine the

![Figure 1](https://example.com/figure1.png)

**Figure 1** Associations of genetic predisposition to allergic disease with esophageal, gastric, and colorectal cancer. BBJ, indicates BioBank Japan; CI, confidence interval; OR, odds ratio; UKBB, UK Biobank

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2020 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd
TABLE 1  
Associations of genetic predisposition to allergic disease with esophageal, gastric, and colorectal cancer in sensitivity analyses

<table>
<thead>
<tr>
<th></th>
<th>Esophageal cancer</th>
<th></th>
<th></th>
<th>Gastric cancer</th>
<th></th>
<th></th>
<th>Colorectal cancer</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR</td>
<td>95% CI</td>
<td>P</td>
<td>OR</td>
<td>95% CI</td>
<td>P</td>
<td>OR</td>
<td>95% CI</td>
<td>P</td>
</tr>
<tr>
<td>UK Biobank</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IVW-fixed effects method</td>
<td>0.89</td>
<td>0.73, 1.08</td>
<td>.242</td>
<td>0.88</td>
<td>0.72, 1.09</td>
<td>.253</td>
<td>0.91</td>
<td>0.84, 0.98</td>
<td>.015</td>
</tr>
<tr>
<td>Weighted median method</td>
<td>0.92</td>
<td>0.69, 1.23</td>
<td>.571</td>
<td>0.84</td>
<td>0.61, 1.15</td>
<td>.270</td>
<td>0.96</td>
<td>0.84, 1.08</td>
<td>.489</td>
</tr>
<tr>
<td>MR-Egger regression</td>
<td>1.01</td>
<td>0.6, 1.68</td>
<td>.976</td>
<td>1.23</td>
<td>0.71, 2.13</td>
<td>.468</td>
<td>0.91</td>
<td>0.73, 1.15</td>
<td>.442</td>
</tr>
<tr>
<td>MR-PRESSO method</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>Heterogeneity</td>
<td>$I^2 = 0%$; Cochrane’s $Q = 114$; $P_{het} = .877$</td>
<td>$I^2 = 0%$; Cochrane’s $Q = 137$; $P_{het} = .393$</td>
<td>$I^2 = 21%$; Cochrane’s $Q = 168$; $P_{het} = .021$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pleiotropy</td>
<td>Intercept = -0.007; $P_{pleiotropy} = .601$</td>
<td>Intercept = -0.018; $P_{pleiotropy} = .208$</td>
<td>Intercept = 0.000; $P_{pleiotropy} = .944$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BioBank Japan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IVW-fixed effects method</td>
<td>0.79</td>
<td>0.66, 0.96</td>
<td>.017</td>
<td>0.88</td>
<td>0.81, 0.96</td>
<td>.004</td>
<td>0.91</td>
<td>0.83, 0.99</td>
<td>.022</td>
</tr>
<tr>
<td>Weighted median method</td>
<td>0.65</td>
<td>0.49, 0.86</td>
<td>.003</td>
<td>0.94</td>
<td>0.82, 1.07</td>
<td>.332</td>
<td>0.87</td>
<td>0.76, 0.99</td>
<td>.034</td>
</tr>
<tr>
<td>MR-Egger regression</td>
<td>0.65</td>
<td>0.37, 1.14</td>
<td>.130</td>
<td>0.83</td>
<td>0.61, 1.13</td>
<td>.237</td>
<td>0.84</td>
<td>0.66, 1.08</td>
<td>.181</td>
</tr>
<tr>
<td>MR-PRESSO method</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>Heterogeneity</td>
<td>$I^2 = 0%$; Cochrane’s $Q = 92$; $P_{het} = .833$</td>
<td>$I^2 = 31%$; Cochrane’s $Q = 154$; $P_{het} = .002$</td>
<td>$I^2 = 3%$; Cochrane’s $Q = 109$; $P_{het} = .407$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pleiotropy</td>
<td>Intercept 0.011; $P_{pleiotropy} = .453$</td>
<td>Intercept 0.003; $P_{pleiotropy} = .682$</td>
<td>Intercept 0.004; $P_{pleiotropy} = .541$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FinnGen consortium</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IVW-fixed effects method</td>
<td>0.93</td>
<td>0.52, 1.67</td>
<td>.803</td>
<td>1.11</td>
<td>0.79, 1.56</td>
<td>.537</td>
<td>0.93</td>
<td>0.79, 1.09</td>
<td>.352</td>
</tr>
<tr>
<td>Weighted median method</td>
<td>0.79</td>
<td>0.34, 1.85</td>
<td>.586</td>
<td>1.21</td>
<td>0.72, 2.02</td>
<td>.477</td>
<td>1.11</td>
<td>0.88, 1.4</td>
<td>.38</td>
</tr>
<tr>
<td>MR-Egger regression</td>
<td>0.30</td>
<td>0.06, 1.43</td>
<td>.129</td>
<td>1.00</td>
<td>0.37, 2.67</td>
<td>.999</td>
<td>0.88</td>
<td>0.55, 1.39</td>
<td>.578</td>
</tr>
<tr>
<td>MR-PRESSO method</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>Heterogeneity</td>
<td>$I^2 = 0%$; Cochrane’s $Q = 81$; $P_{het} = .398$</td>
<td>$I^2 = 14%$; Cochrane’s $Q = 140$; $P_{het} = .103$</td>
<td>$I^2 = 16%$; Cochrane’s $Q = 143$; $P_{het} = .078$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pleiotropy</td>
<td>Intercept 0.061; $P_{pleiotropy} = .127$</td>
<td>Intercept 0.006; $P_{pleiotropy} = .818$</td>
<td>Intercept 0.003; $P_{pleiotropy} = .797$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

There was no corrected estimate (n/a) if no outlier was identified. One outlier was identified and removed in the analysis of colorectal cancer based on UK Biobank ($P$ value for the distortion test was .815) and two outliers were identified and removed in the analysis of gastric cancer based on Biobank Japan ($P$ value for the distortion test was .137).

We observed significant heterogeneity among used SNPs in the analysis of colorectal cancer based on UK Biobank and gastric cancer based on Biobank Japan ($P_{het} < .05$).

Pleiotropy was measured by the intercept from MR-Egger regression. Pleiotropy was not detected in any analysis (all $P > .05$).

causal role of genetic liability to allergic disease in esophageal, gastric, and colorectal cancers.

One hundred and thirty-six single-nucleotide polymorphisms (SNPs) associated with at least one allergic disease (asthma, allergic rhinitis, or eczema) at $P < 3 \times 10^{-8}$ in 180 129 cases and 180 709 non-cases of European ancestry were considered as instrumental variables. The 136 SNPs were independent and not in linkage disequilibrium defined by distance $>1$ Mb and $r^2 < 0.02$. The SNPs explained around 2.6% of phenotypic variance. Summary-level data for the associations of those SNPs with esophageal, gastric, and colorectal cancers were obtained from the UK Biobank, BioBank Japan, and FinnGen consortium. The main analysis was based on the multiplicative random-effects inverse-variance weighted method, and estimates from the different studies were combined using fixed-effects meta-analysis. The inverse-variance weighted method under a fixed effects model and the weighted median, MR-Egger regression, and MR-PRESSO methods were employed as sensitivity analyses. The $I^2$ (%) statistic and Cochrane’s $Q$ value were calculated to assess heterogeneity among estimates of individual SNPs. We considered as strong evidence of causal associations and associations with $P$ values below .017 (where $P = .05/3$) to represent strong evidence of causal associations and associations with $P$ values below .05 but above .017 as suggestive evidence of associations.

Genetic liability to allergic disease was associated with lower risk of the gastrointestinal tract cancers in the meta-analysis of UK
Biobank, BioBank Japan, and FinnGen, though the association with gastric cancer was not statistically significant after correcting for multiple testing (Figure 1). The combined odds ratio was 0.85 (95% confidence interval, 0.75, 0.97; \( P = .016 \)) for esophageal cancer, 0.90 (95% confidence interval, 0.82, 0.98; \( P = .020 \)) for gastric cancer, and 0.91 (95% confidence interval, 0.86, 0.96; \( P = .001 \)) for colorectal cancer for one unit increase in log-transformed odds of allergic disease. The associations were consistent across data sources with the exception of the estimate for gastric cancer in FinnGen which was above one but with a broad confidence interval that overlapped the estimates in UK Biobank and BioBank Japan. Results were consistent in sensitivity analyses for all three cancer outcomes (Table 1).

A potential limitation arises from the fact that we used an instrument for liability to allergic disease that was developed using genetic data from individuals of European ancestry and applied to a Japanese population. However, a consistent effect of risk alleles of SNPs for allergic disease on asthma in BioBank Japan indicates a high validity of used instrumental variables and a negligible population bias. In addition, a robust pattern of established associations in both Asian and European populations suggested that the associations were portable across populations of distinct ancestries. A further limitation of this work is that we cannot make specific inferences about the impact of food allergies on cancer risk.

In summary, this MR study supports a protective effect of allergic disease against esophageal and colorectal cancer and possibly gastric cancer. This finding may be useful for further laboratory studies to understand the immunological pathways involved in gastrointestinal tract carcinogenesis.

ACKNOWLEDGMENTS

Genetic instruments for allergic disease were obtained from a published meta-analysis of genome-wide association studies. Genetic association estimates for esophageal, gastric, and colorectal cancers were obtained from the UK Biobank study, BioBank Japan, and FinnGen consortium. The authors thank all investigators for sharing these data. Analyses of UK Biobank data were performed under application 29202.

CONFLICT OF INTEREST

The authors report no conflicts of interest.

ETHICAL APPROVAL

All studies included in cited genome-wide association studies had approved by a relevant review board. The present MR analyses were approved by the Swedish Ethical Review Authority (2019-02793).

FUNDING INFORMATION

SK is supported by a Cancer Research UK program grant, the Integrative Cancer Epidemiology Programme (C18281/A19169), AMM is supported by EC-Innovative Medicines Initiative (BigData@Heart). SB is supported by Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (204623/Z/16/Z). SCL is supported by research grants from the Swedish Research Council for Health, Working Life and Welfare (Forte; grant no. 2018-00123), the Swedish Research Council (Vetenskapsrådet; grant no. 2019-00977), and the Swedish Heart-Lung Foundation (Hjärt-Lungfonden; grant no. 20190247). This work is supported by funding from the National Institute for Health Research (to SB) [Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust] [*]. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Shuai Yuan1
Mathew Vithayathil2
Siddhartha Kar3
Paul Carter4
Amy M. Mason5,6
Shao-Hua Xie7
Stephen Burgess4,8
Susanna C. Larsson1,9

1Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
2MRC Cancer Unit, University of Cambridge, Cambridge, UK
3MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, UK
4Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
5British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
6National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge and Cambridge University Hospitals, Cambridge, UK
7Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
8MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
9Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

Correspondence

Susanna C. Larsson, Institute of Environmental Medicine, Karolinska Institutet, Nobelsväg 13, Stockholm, 17177, Sweden; Department of Surgical Sciences, Uppsala University, Dag Hammarskjölds Väg 14B, Uppsala, 75185, Sweden.
Email: susanna.larsson@ki.se

ORCID

Shuai Yuan https://orcid.org/0000-0001-5055-5627
Susanna C. Larsson https://orcid.org/0000-0003-0118-0341
REFERENCES


SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.